摘要:
This invention relates to antibiotic compounds AA896 of the formula 1 wherein: R1 is H, aryl, alkyl (C1-C20), nullCH2-aryl, nullC(O)alkyl(C1-C20), nullC(O)NHalkyl(C1-C20), or nullC(O)NHaryl; R2 is H, alkyl (C1-C20), nullCH2aryl, alkyl (C1-C20) or nullC(O)alkyl(C1-C20); R3 is nullOH; R2 and R3 may optionally be taken together to form a moiety 2 R4 is alkyl (C1-C20), or aryl; or a pharmaceutically acceptable salt thereof.
摘要:
An efficient method for producing cytidine derivatives that took away the previous drawbacks by efficiently synthesizing cytidine derivatives by utilizing a tertiary amine can be provided.
摘要:
The application relates to compounds that are suitable as labelable precursors for synthesis of 3null-null18Fnullfluoro-3null-deoxythymidine and that have formula (1), 1 in which R denotes triphenylmethyl, triphenylmethyl substituted in the phenyl group, trialkylmethyl, triphenylsilyl, triphenylsilyl substituted in the phenyl group, or trialkylsilyl, Rnull denotes R1nullSO2, where R1 is an unsubstituted or substituted C1 to C5 alkyl or an unsubstituted or substituted phenyl, and Rnull denotes C2 to C10 alkyloxycarbonyl, with the exception of 3-N-Boc-1-(3-O-nosyl-5-O-trityl-2-deoxy-null-D-lyxofuranosyl)thymine. The application also relates to a method for preparation of these compounds and to the use of the same for synthesis of 3null-null18Fnullfluoro-3null-deoxythymidine.
摘要:
A compound of formula (I) 1 wherein R1 and R2 represent a hydrogen atom or an aryl, a heterocyclic, an alkyl or an alkenyl, which are optionally substituted, R3 represents a hydrogen atom or a hydroxyl and X1 and X2 represent an oxygen atom, a sulfur atom or a nitrogen containing group, a pharmaceutically acceptable derivative thereof or a salt thereof. A pharmaceutical composition comprising the compound for the prevention or treatment of a bacterial infection. A method for the prevention or treatment of a bacterial infection in a warm-blooded animal comprising administering a pharmacologically effective amount of the compound.
摘要翻译:式(I)的化合物,其中R 1和R 2表示氢原子或任选被取代的芳基,杂环,烷基或链烯基,R 3表示氢原子或羟基 X 1和X 2表示氧原子,硫原子或含氮基团,其药学上可接受的衍生物或其盐。 一种药物组合物,其包含用于预防或治疗细菌感染的化合物。 一种预防或治疗温血动物细菌感染的方法,包括施用药理学有效量的化合物。
摘要:
A compound of formula 1-null3,4-dihydroxy-5-(2-hydroxyethyl) tetrahydrofuran-2-ylnullpryimidine-2,4(1H,3H)-dione has inhibitory effects of matrix metalloproteinase-2 (gelatinase A) enzyme and binding of TNFnull to TNFnull-RI.
摘要:
The invention provides compounds of the Formula 1 1 wherein the definitions of m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 are in the specification. These compounds are useful as antibacterial agents.
摘要:
Antibiotics RK-1061s having a novel chemical structure and a method of production thereof. They have a structural formula represented by general formula(I) wherein A represents R1 or R1CH(OR2)CH2. R2 represents 3-methylglutarie acid residue and R3 represents a sulfate group or a hydrogen atom. The process comprises culturing a ray fungus belonging to the genus Streptomyces and isolating RK-1061s from the culture. Streptomyces sp. SN-1061Ms (FERM BP-5800) is capable of stably producing RK-1061 at a high productivity. 1
摘要:
Provided is a single-step process for the selective 3null-acylation of a ribofuranosyl 2null or 3null-branched nucleoside. These compounds are useful as antiviral agents, and in particular, can be used to treat Flaviviridae infections in a host in need thereof.
摘要:
The present invention relates to nucleoside derivatives for the treatment of Hepatitis C viral infections including compounds of formula I, pharmaceutical compositions comprising these compounds and methods for treatment or prophylaxis of Hepatitis C Virus mediated diseases employing said compounds in monotherapy or in combination therapy. The present invention further provides a process for preparing 1null,3null,4null-triacyl pyrimidine nucleoside from a N, 1null,3null,4null-tetraacylpyrimidine nucleoside 1
摘要:
The present invention provides crystalline forms and compositions thereof, of a pyrimidine nucleoside derivative of formula (I) having anti-tumour activity, wherein formula (I) is: 1